Osteolytic bone resorption in adult T-cell leukemia/lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 4, 2010, Pages 702-714

  Shu, Sherry T ^a   Martin, Chelsea K ^a   Thudi, Nanda K ^a   Dirksen, Wessel P ^a   Rosol, Thomas J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

ATLL; MIP 1 ; OPG; Osteolytic bone resorption; PTHrP; RANKL

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALVARIA; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HYPERCALCEMIA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T CELL LEUKEMIA; T LYMPHOCYTE;

ADULT; ANIMALS; ANIMALS, NEWBORN; BONE RESORPTION; CALCIUM; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, NEOPLASTIC; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JURKAT CELLS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; OSTEOLYSIS;

EID: 77953215089     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003646697     Document Type: Article

References (45)

1. Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord 2000;1:253-263.
2. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005;24:6047-6057.
3. Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 2006;18(4):396-404.
4. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-2617.
5. Shibata H, Abe M, Hiura K, et al. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factorkappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clin Cancer Res 2005;11:6109-6115.
6. Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 2004;104:802-809.
7. Feuer G, Zack JA, Harrington WJ, Jr., et al. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood 1993;82:722-731.
8. Richard V, Nadella MV, Green PL, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia 2005;19:1175-1183.
9. Luchin A, Suchting S, Merson T, et al. Genetic and physical interactions between microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J Biol Chem 2001;276:36703- 36710.
10. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001;97: 3349-3353.
11. Richard V, Luchin A, Brena RM, Plass C, Rosol TJ. Quantitative evaluation of alternative promoter usage and 30 splice variants for parathyroid hormone-related protein by real-time reverse transcription-PCR. Clin Chem 2003;49: 1398-1402.
12. Holven KB, Damas JK, Yndestad A, et al. Chemokines in children with heterozygous familiar hypercholesterolemia: selective upregulation of RANTES. Arterioscler Thromb Vasc Biol 2006;26:200-205.
13. Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res 2004;19:1105-1111.
14. Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac (null) mice: suppression by an inhibitor against NF-kappaB. J Virol 2003;77:5286-5294.
15. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990;87:4473-4475.
16. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002;99:634-640.
17. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5(Suppl. 2): S46-S53.
18. Shen X, Falzon M. PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol Cell Endocrinol 2003;199:165-177.
19. Nakashima M, Ohtsuru A, Luo WT, et al. Expression of parathyroid hormone-related peptide in human thyroid tumours. J Pathol 1995;175:227-236.
20. Ikeda K, Inoue D, Okazaki R, Kikuchi T, Ogata E, Matsumoto T. Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormonerelated peptide overexpression in HTLV-I-infected T cells. Miner Electrolyte Metab 1995;21:166-170.
21. Liao J, McCauley LK. Skeletal metastasis: established and emerging roles of parathyroid hormone-related protein (PTHrP). Cancer Metastasis Rev 2006;25:559-571.
22. Richard V, Rosol TJ, Foley J. PTHrP gene expression in cancer: do all paths lead to Ets? Crit Rev Eukaryot Gene Expr 2005;15:115-132.
23. Nadella MV, Dirksen WP, Nadella KS, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia 2007;21:1752-1762.
24. Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002;100:4129-4138.
25. Terpos E, Anagnostopoulos A, Kastritis E, Bamias A, Tsionos K, Dimopoulos MA. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia. Br J Haematol 2006;133:301-304.
26. Mori K, Chano T, Yamamoto K, Matsusue Y, Okabe H. Expression of macrophage inflammatory protein-1alpha in Schwann cell tumors. Neuropathology 2004;24:131-135.
27. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
28. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-1841.
29. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-319.
30. Henderson JE, Amizuka N, Warshawsky H, et al. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 1995;15:4064-4075.
31. Zheng F, Liang H, Liu R, et al. Parathyroid hormone-related protein regulates osteoclast inhibitory lectin expression via multiple signaling pathways in osteoblast-like cells. Endocrine 2009;35:47-56.
32. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoidinduced osteoporosis. Endocrinology 1999;140:4382-4389.
33. Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. J Cell Biochem 2001;84:1-11.
34. Thirunavukkarasu K, Miles RR, Halladay DL, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 2001;276:36241-36250.
35. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTHinduced cortical bone loss through CD40L signaling. Cell Metab 2008;8:132-145.
36. Ortega N, Behonick D, Stickens D, Werb Z. How proteases regulate bone morphogenesis. Ann NY Acad Sci 2003;995:109-116.
37. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 2004;50:87-100.
38. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005;142:12-20.
39. Giraudon P, Vernant JC, Confavreux C, Belin MF, Desgranges C. Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology 1998;50:1920.
40. Giraudon P, Szymocha R, Buart S, et al. T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-Iinduced neurological disease. J Immunol 2000;164:2718-2727.
41. Mori N, Sato H, Hayashibara T, et al. Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood 2002;99:1341-1349.
42. Cho NH, Hong KP, Hong SH, Kang S, Chung KY, Cho SH. MMP expression profiling in recurred stage IB lung cancer. Oncogene 2004;23:845-851.
43. Miyata Y, Iwata T, Maruta S, et al. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol 2007;52:791-797.
44. Mathew R, Khanna R, KumarR, et al. Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev 2002;26:222-228.
45. Haeusler G, Walter I, Helmreich M, Egerbacher M. Localization of matrix metalloproteinases (MMPs), their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth plates of children and adolescents indicates a role for MMPs in human postnatal growth and skeletal maturation. Calcif Tissue Int 2005;76:326-335.